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Intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) are 3 therapeutic antibody products derived from the pooled plasma of donors. Indications for 4 use are as replacement therapy in antibody-deficiency syndromes (including 'primary' 5 disorders such as Common Variable Immunodeficiency (CVID) and 'secondary' to other 6 illnesses and medications, including haematological malignancy) or, in higher doses, as 7 immunomodulatory treatment for autoimmune and autoinflammatory conditions (for 8 example idiopathic thrombocytopenic purpura [1] ). 9 These products may contain clinically important antibodies which the recipient did not 10 previously produce. Although IgG serology is not generally used to diagnose acute or active 11 infection, there are situations where evidence of past infection significantly alters clinical 12 management. Most importantly, antibodies against Hepatitis B virus (HBV) are measured 13 when commencing certain immunosuppressive treatments (especially the anti-CD20 14 monoclonal antibody rituximab) due to the risk of HBV reactivation; a positive result in this 15 context would prompt commencement of prophylactic antiviral medication. Two major 16 anti-HBV antibodies are measured: surface antibody (sAb), which is generated in response 17 to HBV vaccination, and core antibody (cAb), interpreted as a marker of current or past HBV 18 infection [2] . 19 It has been suggested that HBV antibodies are transmitted to recipients via IVIG [3] [4] [5] . 20 However, these descriptions are limited to case reports plus one series of 11 patients [4] 21 and the issue has never been systematically studied: in particular, the rate of transmission, 22 time to seroconversion, whether patients sero-revert to negative while receiving IVIG 23 treatment, differences according to infused product and the overall prevalence of these 24 antibodies in immunoglobulin-treated patients are unknown. Consequently, physicians 25 remain unaware of this issue, with recent case reports describing the phenomenon as a 26 novel finding [3, 5] . 27 Another diagnostic test which may be confounded by immunoglobulin treatment is the patients, especially those with neutropenia or undergoing stem cell transplant [6] . It has 32 been suggested in one abstract that IVIG products and their stabilisers may yield false-33 positive results using the GM-EIA [7] . However, this phenomenon has also not been 34 systematically evaluated. 35 We therefore undertook studies to address these deficiencies in the literature: a cross- 
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For the cross-sectional study, patients were eligible if established on IVIG or SCIG treatment 43 (>6 months), had baseline serum stored pre-IVIG and had not received IVIG within 6 Privigen® were taken at least 27 days since the last infusion ( Figure 2D) Figure S2 ). For example, neat Kiovig® has been reported to test positive for cAb [5] but no patients in 189 our cohort receiving Kiovig® yielded positive results. We hypothesise that this reflects lower 190 cAb concentration in this product and thus a higher dose threshold for transmission. 191 Importantly, it may still be possible to acquire false-positive cAb results from Kiovig® (and 192 perhaps Intratect®) if receiving high-dose IVIG and tested soon after infusion. 
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The cause of the GM-EIA positivity is unclear. There was no evidence of fungal growth or 217 PCR positivity in the products, excluding gross fungal contamination. The stabilisers used in 218 products testing positive are not known to confound the assay, and we did not recapitulate 219 the previous finding that only sorbitol-stabilised products were positive [7] . Glycine was a Our study has limitations. Numbers of patients on some subcutaneous products were small. 230 We cannot definitively prove passive HBV cAb acquisition in the cross-sectional study, but 231 with an annual incidence of HBV infection of 2 per 100,000 in London [15] , true infection 232 seems extremely unlikely. In the prospective study, absence of surface antigen and 
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Mean Serum from 28 patients receiving IVIG products whose neat contents tested positive (> 0.5) for GM EIA (Flebogamma® DIF, Gammaplex®, Intratect®, Kiovig®) was tested immediately before and after infusion using the BioRad Galactomannan Immunoassay. Lines represent medians. The dotted line represents the threshold for a patient's result to be declared 'positive'. ** p<0.01, Mann-Whitney test. B. Serum from 9 patients receiving IVIG products whose neat contents tested negative (> 0.5) for GM EIA (Octagam®, Privigen®) was tested immediately before and after infusion using the BioRad Galactomannan Immunoassay. Lines represent medians. The dotted line represents the threshold for a patient's result to be declared 'positive'.
